Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of recombinant human
interferon-α1b (IFN-α1b) combined with toripalimab and anlotinib hydrochloride in patients
with unresectable advanced melanoma. This study consists of 2 phases（ Ib / II）. Phase Ib will
determine the recommended phase Ⅱ dose for anlotinib hydrochloride. Phase II will evaluate
the efficacy and safety of the triple combination regimens.